In the United States, clinical trials have long been criticized for inadequate inclusion of minority patients and consequently for not representing the country’s diverse population. The FDA recently released new…
Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR…
The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT US Pharma and Biotech Summit…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
The pandemic revealed widespread pharmaceutical supply chain vulnerabilities in the United States, an issue the Biden administration has attempted to address partly through industry funding. The Chief Business Officer of…
After five years in China, Rogier Janssens goes on to lead Latin America Healthcare for EMD Serono. Rogier Janssens, former General Manager of the biopharma business of Merck KGaA, Darmstadt,…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
Sparks, the Swiss Exchange’s newly launched small and medium sized enterprise (SME) trading venue, intends to make it easier for biotech SMEs to raise capital and strengthen their profile. The…
A snapshot of Germany, one of the European pharma hotspots featured in PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022. With the largest market value in Europe, Germany remains at…
Public trust in the COVID-19 supply chain has grown, but there is still a strong need for standards, processes, and capabilities to ensure patients across the globe have access to…
The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
See our Cookie Privacy Policy Here
